List of new antibiotics approved since 2000

List of antibiotics,  since 2000:

 2000: Linezolid (Zyvox) — The first oxazolidinone, a new class effective against vancomycin-resistant enterococci (VRE) and MRSA.

2003: Daptomycin (Cubicin) — The first lipopeptide approved for skin and skin structure infections.

2005: Tigecycline (Tygacil) — First glycylcycline, a derivative of minocycline designed to overcome resistance. 

2010: Ceftaroline fosamil (Teflaro) — First cephalosporin with activity against MRSA.

2011: Fidaxomicin (Dificid) — A macrocyclic antibiotic for Clostridioides difficile.

2012: Bedaquiline (Sirturo) — First diarylquinoline for multi-drug resistant tuberculosis (MDR-TB).

2014: Dalbavancin (Dalvance) & Oritavancin (Orbactiv) — Lipoglycopeptides for acute bacterial skin and skin structure infections (ABSSSI).

2014: Tedizolid (Sivextro) — A second-generation oxazolidinone.

2014: Ceftolozane/tazobactam (Zerbaxa) — Cephalosporin/β-lactamase inhibitor combination.

2015: Ceftazidime/avibactam (Avycaz) — Novel β-lactamase inhibitor combination for serious Gram-negative infections.

2017: Meropenem/vaborbactam (Vabomere) — Combination targeting carbapenem-resistant Enterobacteriaceae (CRE).

2017: Delafloxacin (Baxdela) — An anionic fluoroquinolone with activity against MRSA.

2017: Ozenoxacin (Ozanex) — Topical quinolone.

2018: Plazomicin (Zemdri) — Next-generation aminoglycoside.

2018: Eravacycline (Xerava) — Novel synthetic fluorocycline.

2018: Omadacycline (Nuzyra) — Aminomethylcycline for pneumonia and skin infections.

2018: Sarecycline (Seysara) — Tetracycline for acne.

2019: Cefiderocol (Fetroja) — Siderophore cephalosporin for MDR Gram-negative infections.

2019: Lefamulin (Xenleta) — First systemic pleuromutilin for community-acquired pneumonia (CABP).

2019: Pretomanid — Nitroimidazole for extensively drug-resistant TB (XDR-TB)

 

The Threat: Microbes change over time, rendering drugs ineffective and leading to "superbugs".

Causes: Overuse of antibiotics for viral infections (like colds/flu), not finishing prescribed courses, and environmental contamination.

Prevention: Proper antimicrobial stewardship, including only using them when prescribed and practicing good hygiene to prevent infections.

 

 Thanks to Microbiology Matters for the list. 

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)